JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Viatris Inc

Închisă

SectorSănătate

10.36 0.58

Rezumat

Modificarea prețului

24h

Curent

Minim

10.3

Maxim

10.49

Indicatori cheie

By Trading Economics

Venit

3B

-4.6M

Vânzări

328M

3.6B

Randament dividend

4.72

Marjă de profit

-0.128

Angajați

32,000

EBITDA

2.9B

578M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+10.47% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.72%

2.33%

Următoarele câștiguri

6 nov. 2025

Data viitoare de dividende

12 dec. 2025

Următoarea dată ex-dividende

21 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.5B

12B

Deschiderea anterioară

9.78

Închiderea anterioară

10.36

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Viatris Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 oct. 2025, 09:10 UTC

Acțiuni populare

Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials -- WSJ

Comparație

Modificare preț

Viatris Inc Așteptări

Obiectiv de preț

By TipRanks

10.47% sus

Prognoză pe 12 luni

Medie 11.5 USD  10.47%

Maxim 15 USD

Minim 8 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruViatris Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

4 ratings

1

Cumpărare

2

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

8.48 / N/ASuport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Strong Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat